fda bars generic oxy contin-ny times, page-15

Well perhaps JF , I know David well & used him as a broker for many years . You can bet his lost his voice to brokers & fund managers .
I really think its up to the scientists to get on soap box's . The American Pain Society conference in New Orleans next month may have been a good place to start . The lack of publishing & presenting in the last 5 years has us off the radar to our target audience imo .
Mind you I wouldn't care if there were some/any evidence of big pharma lurking re' oxtpatch . I would have thought now would be the time to strike with the leg up from Novartis .